What is the treatment approach for adenovirus infections in infants?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Adenovirus in Infants

For immunocompetent infants with adenovirus infection, supportive care alone—including hydration, antipyretics, and respiratory support as needed—is the recommended treatment, with cidofovir reserved exclusively for life-threatening infections in severely ill or immunocompromised infants. 1, 2

Supportive Care for Immunocompetent Infants

The cornerstone of management for the vast majority of infants with adenovirus infection is supportive care, as the infection typically resolves within 7-10 days without specific antiviral therapy. 1

Key supportive measures include:

  • Adequate hydration to maintain fluid balance 1
  • Antipyretics for fever management 1
  • Respiratory support (oxygen, nebulizers) as clinically indicated 1
  • Close monitoring for clinical deterioration over the typical 7-10 day illness course 1, 2

No specific antiviral therapy is indicated for self-limited gastroenteritis or upper respiratory infections in immunocompetent infants. 2

Cidofovir for Severe or Life-Threatening Infections

Cidofovir is the treatment of choice for severe adenovirus infections, particularly in immunocompromised infants or those with disseminated disease. 1, 2 This recommendation stands despite the lack of randomized controlled trials. 2

Dosing regimen:

  • 5 mg/kg IV once weekly for 2 weeks, then every other week 1, 2
  • Mandatory renal function monitoring is essential due to considerable nephrotoxicity risk 1, 2

Recent real-world data from 2022 showed cidofovir was used in 21 children with severe adenovirus infection (including 11 previously healthy children) without attributed side effects, though this was in a PICU setting. 3

High-Risk Populations Requiring Vigilance

Infants at highest risk for severe disease include:

  • Age under 1 year with myocarditis: 5-year survival rate of only 66% with adenovirus versus 95% without 1, 2
  • Immunocompromised status: fatality rates exceeding 50% for untreated severe pneumonia or disseminated disease 1, 4
  • Adenovirus serotypes 3 and 7: associated with worse prognosis 1, 2

Infection Control Measures

Critical infection control practices:

  • Infants are infectious for 10-14 days from symptom onset 1, 2
  • Hand hygiene with soap and water is essential (adenovirus survives on surfaces up to 28 days) 2
  • Dilute bleach solution for equipment and surface disinfection 1, 2
  • Isolation in hospitals and daycare settings to prevent outbreaks 1, 2

Special Clinical Scenarios

For adenoviral conjunctivitis in infants:

  • Symptomatic relief with artificial tears and topical antihistamines 1
  • Topical corticosteroids may be indicated for severe cases with marked chemosis, lid swelling, epithelial sloughing, or membranous conjunctivitis 1

Critical Pitfalls to Avoid

Avoid unnecessary antibiotic use: In one study, 46% of adenovirus-positive children received antibiotics at presentation, but only 1.4% had documented bacterial infection. 5 Identifying adenovirus can prevent unnecessary antibiotic therapy. 5

Do not delay cidofovir in severe cases: For immunocompetent infants with fulminant presentations (such as liver failure), early cidofovir treatment based on rapid diagnostic testing can be life-saving. 5 One case report documented recovery from fulminant liver failure after cidofovir treatment, avoiding liver transplant. 5

Consider adenovirus in differential diagnosis: When infants present with fever ≥5 days, particularly with conjunctivitis, pharyngitis, or respiratory symptoms, adenovirus should be considered. 2 This is especially important to differentiate from Kawasaki disease, where withholding immune globulin may be appropriate if adenovirus is confirmed. 5

References

Guideline

Adenovirus Infection Management in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Adenovirus in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Adenovirus: Epidemiology, Global Spread of Novel Types, and Approach to Treatment.

Seminars in respiratory and critical care medicine, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.